Issue 16 | February 2019

catabasis CONNECTION

Updates on edasalonexent and clinical trials

The Phase 3 PolarisDMD Trial Goes Global!

With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have launched. Sites are also expected to launch soon in Europe and Israel.

Enrollment in the PolarisDMD trial is off to a great start. As a reminder, if you'd like to learn more, contact us at **DMDtrials@catabasis.com**



A SPECIAL THANK YOU TO OUR MOVEDMD FAMILIES!

We would like to extend our deepest gratitude to the boys, families, caregivers and trial sites participating in our Phase 2 MoveDMD clinical trial and open-label extension. It is your commitment and involvement that has enabled us to successfully launch the PolarisDMD Phase 3 trial. Here are some statistics that highlight our MoveDMD trial and participants.

Move DMD

Families flew more than 3 million miles to site visits — that's equivalent to 12 trips to the moon!



A total of 26 different DMD gene mutations were represented in 31 boys, suggesting that edasalonexent has potential to treat everyone affected by Duchenne.



Boys are growing taller! Boys grew over 2 inches per year on average, which is comparable to the growth curves of boys not affected by Duchenne.

A total of 260 visits to trial sites attended, and no Serious Adverse Events recorded in 55 patient-years of treatment.

POTENTIAL BONE HEALTH BENEFITS OF EDASALONEXENT

Why is bone health so important in Duchenne?

- Boys with Duchenne are at an increased risk of bone fractures and should be monitored yearly to check for fractures. Early detection is critical.
- Strong bones are important to help boys grow taller!
- Some therapies used to treat Duchenne have an additional negative impact on bone health and can increase the frequency of long bone and spine fractures.

We believe that edasalonexent has the potential to benefit bone health, which is why we are studying it in our Phase 3 PolarisDMD trial. Because edasalonexent is an NF-kB inhibitor, it has the potential to reduce inflammation and promote muscle regeneration, and that can strengthen bones. We will perform x-rays and body scans at the beginning and end of the study to check on bone health!

About edasalonexent (CAT-1004)

Edasalonexent inhibits NF-kB, a protein which plays a fundamental role in skeletal and muscle disease in DMD. By inhibiting NF-kB, edasalonexent has the potential to decrease inflammation and fibrosis, promote muscle regeneration, and slow disease progression. Edasalonexent was designed as a stand-alone therapy and may also enhance the efficacy of dystrophin upregulation therapies.

MAKING COMMUNITY CONNECTIONS

Jett Foundation Family Workshops—This national education program brings together clinicians, researchers, and families affected by Duchenne to learn about care, crucial information, and resources. Coming up, Catabasis will attend workshops held in **Little Rock, Arkansas on March 9, and Phoenix, Arizona on March 23**.

PPMD End Duchenne Tour—In an effort to reach every single family facing a Duchenne diagnosis in the US, PPMD hosts a community experience called the *End Duchenne Tour* to bring updates on research, advocacy, and care. Catabasis will be on the tour in **Omaha, Nebraska on March 30**.

CureDuchenne Cares—These events provide an immersive education experience where clinicians and experts share their wealth of Duchenne knowledge and advancements in the field. Caregivers learn about physical therapy, get important updates about clinical trials, and learn valuable best practices in Duchenne care. Catabasis will attend in **Columbia, Missouri on March 16**.

Stay in touch!

Join our mailing list: http://www.catabasis.com/patients-families/for-further-information.php
Follow us on social media: @CatabasisPharma.
Ask a question about the trial: DMDtrials@catabasis.com

The information provided here is for parents and caregivers of boys with Duchenne muscular dystrophy (DMD). Edasalonexent is an investigational drug that is not yet FDA approved.

catabasis

POLARIS DMD